520 completed, 57 unknown, 49 terminated, 22 withdrawn. 678 Phase 3, 64 Phase 2.
Follow Hepatitis, Viral, Human: new trials by email Literature Review of Hepatitis, Viral, Human trials Research Report on Hepatitis, Viral, Human
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D Hepalatide 2.1mg, Placebo of Hepalatide - Hepatitis D, Chronic | Phase 3 | Not yet recruiting | Shanghai HEP Pharmaceutical Co., Ltd. | 150 | 2027-06-01 | 2026-10-28 |
| Study Interchangeability Hep-B Vaccine Administered at Birth Dose In-house Hepatitis B Vaccine, Registered Hepatitis B Vaccine - Vaccination Adverse Event, Immunogenicity, Vaccine | Phase 3 | Not yet recruiting | PT Bio Farma | 270 | 2026-10-01 | 2026-10-02 |
| Study of BK1803 in Healthy Infants BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection - Pertussis, Diphtheria | Phase 3 | Not yet recruiting | Tanabe Pharma Corporation | 344 | 2026-10-01 | 2026-08-28 |
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
| Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response TQA3605 tablets Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis B | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 930 | 2026-09-01 | 2026-10-02 |
| Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package - HIV Infection, Sexually Transmitted Infection | Phase 3 | Not yet recruiting | HIV Prevention Trials Network | 400 | 2026-09-01 | 2026-06-22 |
| Phase IIIB Extension Clinical Trial of Efficacy and Safety of GST-HG141 (Nairevir) Combined With NAs in Chronic Hepatitis B GST-HG141 - Chronic Hepatitis b | Phase 3 | Not yet recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 576 | 2026-06-26 | 2026-05-14 |
| A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study) Libevitug 20 mg/kg, Libevitug 10 mg/kg, Delayed treatment with libevitug - Chronic Hepatitis D Infection | Phase 3 | Recruiting | Huahui Health | 160 | 2026-04-22 | 2026-08-24 |
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Brelovitug (BJT-778), Bulevirtide - Chronic Hepatitis D | Phase 2 / Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 120 | 2026-02-26 | 2026-10-27 |
| A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg - Chronic Hepatitis D Infection | Phase 3 | Active not recruiting | Mirum Pharmaceuticals, Inc. | 80 | 2026-01-14 | 2026-06-29 |
| Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) Recombinant Hepatitis B new Bulk vaccine, DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine, Recombinant Hepatitis B vaccine (Registered BioFarma) - Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction | Phase 3 | Withdrawn | PT Bio Farma | 2025-12-01 | 2025-06-05 | |
| Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) In-House Recombinant Hepatitis B (Bio Farma) vaccine, Registered Hepatitis B vaccine recombinant (Engerix-B) - Vaccine Reaction, Vaccine Adverse Reaction | Phase 3 | Not yet recruiting | PT Bio Farma | 540 | 2025-09-01 | 2025-06-06 |
| A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B AZVUDINE, TAF, IFNα-2a - Chronic Hepatitis B, Azvudine | Phase 3 | Recruiting | Zhigang Ren | 120 | 2025-09-01 | 2025-12-29 |
| A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg - Chronic Hepatitis D Infection | Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 172 | 2025-08-27 | 2026-10-08 |
| Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) AHB-137, Placebo, NA therapy - Chronic Hepatitis B | Phase 3 | Active not recruiting | Ausper Biopharma Co., Ltd. | 577 | 2025-08-12 | 2026-05-04 |
| A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB ZM-H1505R 100mg, ZM-H1505R Placebo, NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF"） treatments - Chronic Hepatitis B | Phase 3 | Not yet recruiting | Shanghai Zhimeng Biopharma, Inc. | 1300 | 2025-08-01 | 2025-08-03 |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 150 | 2025-07-30 | 2026-07-13 |
| To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment GST-HG141, GST-HG141 Placebo - Chronic Hepatitis b | Phase 3 | Recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 526 | 2025-07-24 | 2026-01-23 |
| A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B HTS 20mg, HTS 30mg, HTS 40mg - Chronic Hepatitis B | Phase 2 / Phase 3 | Active not recruiting | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 1444 | 2025-07-01 | 2025-10-02 |
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir - HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic | Phase 3 | Active not recruiting | Atea Pharmaceuticals, Inc. | 880 | 2025-06-02 | 2026-06-29 |
Showing 20 of 678. Sign in to see all of them.
Hepatitis C (284) · Hepatitis C, Chronic (201) · Hepatitis B (195) · Hepatitis B, Chronic (85) · Diphtheria (57) · Tetanus (56) · Haemophilus Infections (47) · Whooping Cough (44) · Poliomyelitis (37) · Fibrosis (33) · Hepatitis (33) · HIV Infections (25) · Hepatitis A (21) · Liver Diseases (18) · Virus Diseases (18)
Digestive System Diseases (672) · Infections (671) · Liver Diseases (660) · Virus Diseases (660) · Blood-Borne Infections (650) · Communicable Diseases (647) · Hepatitis (645) · RNA Virus Infections (474) · Flaviviridae Infections (389) · Pathological Conditions, Signs and Symptoms (332) · Pathologic Processes (330) · Disease Attributes (308) · Chronic Disease (300) · Hepatitis, Chronic (286)
Ribavirin (198) · peginterferon alfa-2a (103) · peginterferon alfa-2b (60) · Sofosbuvir (49) · Tenofovir (32) · daclatasvir (32) · ombitasvir (32) · paritaprevir (30) · glecaprevir and pibrentasvir (28) · dasabuvir (27) · Hepatitis B Vaccines (25) · entecavir (24) · telaprevir (23) · glecaprevir (22) · Engerix-B (21)
GlaxoSmithKline (68) · Merck Sharp & Dohme LLC (60) · Gilead Sciences (49) · AbbVie (48) · Bristol-Myers Squibb (39) · Sanofi Pasteur, a Sanofi Company (25) · Hoffmann-La Roche (15) · French National Agency for Research on AIDS and Viral Hepatitis (11) · Boehringer Ingelheim (10) · Janssen R&D Ireland (9) · Novartis Pharmaceuticals (9) · Tanabe Pharma Corporation (9) · Foundation for Liver Research (7) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (7) · Novartis (7)
United States (176) · Canada (106) · France (106) · Germany (93) · Spain (89) · United Kingdom (81) · Italy (71) · Australia (70) · Belgium (61) · Puerto Rico (59) · South Korea (59) · China (58) · Poland (51) · Russia (51) · Taiwan (47)
PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 29461687, PMID 30529905, PMID 29377566, PMID 29404492, PMID 28193518, PMID 25040192, PMID 25583164, PMID 27847279, PMID 30868245, PMID 35174470, PMID 25445400, PMID 26743093, PMID 26947564, PMID 27553375, PMID 36740893, PMID 17716936, PMID 19052126, PMID 20189674, PMID 20955704, PMID 22239511, PMID 22626609, PMID 23234725, PMID 23364953, PMID 23607593, PMID 23607594, PMID 23939953, PMID 24126097, PMID 25179493, PMID 25196718, PMID 25277773, PMID 25532501, PMID 25710287, PMID 25777337, PMID 25788199, PMID 25987775, PMID 26173631, PMID 26321288, PMID 26575258, PMID 26683763, PMID 26936417, PMID 27049487, PMID 27658343, PMID 27920566, PMID 28215615, PMID 28390869, PMID 28564569
2015 (23), 2014 (21), 2016 (10), 2004 (6), 2008 (4), 2009 (4), 2005 (3), 2017 (3), U01DK082843 (3), U01DK082864 (3), U01DK082871 (3), U01DK082874 (3), U01DK082944 (3), UL1TR000004 (3), M01RR000040 (2)